Physician profile
Alexander Balaez
NPI 1972134286
$7,962.27
in general payments reported to CMS, 2019-2025
33 companies · $1,102 in 2025
The $1,102 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,998 · 2022: $2,145 · 2023: $1,132 · 2024: $1,586 · 2025: $1,102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,820.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,819.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,985.62 | 2021-2025 | Watchman Flx, General - Ultrasound, General - Therapies |
| Amgen INC. | $935.57 | 2021-2024 | Repatha |
| Impulse Dynamics (USA) INC. | $883.87 | 2022-2024 | Optimizer, Optimizer |
| Abbott Laboratories | $595.24 | 2021-2025 | Gallant, Jot Dx, Thoratec Heartmate 3 Lvas Implant Kit |
| Cleerly, INC. | $580.42 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Atricure, INC. | $371.42 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $358.29 | 2021-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $296.38 | 2022-2025 | Farxiga, Wainua |
| Zoll Circulation INC | $287.00 | 2021 | |
| Pfizer INC. | $282.10 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $215.50 | 2021-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $184.24 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $151.95 | 2022-2025 | Camzyos, Eliquis |
| Medtronic, INC. | $136.45 | 2024 | Cobalt Dr Mri Surescan |
| Esperion Therapeutics, INC. | $123.80 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $121.56 | 2023 | |
| Osprey Medical INC | $116.26 | 2021 | |
| Kestra Medical Technology Services, INC. | $37.57 | 2024 | Assure Wcd |
| Edwards Lifesciences Corporation | $30.63 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $27.32 | 2024 | Lifevest |
| Lexicon Pharmaceuticals, INC. | $23.70 | 2023 | Inpefa |
| Xeris Pharmaceuticals, INC. | $22.66 | 2025 | Keveyis |
| Kiniksa Pharmaceuticals International, Plc | $21.75 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.98 | 2024 | Jardiance |
| Daiichi Sankyo INC. | $19.78 | 2022 | |
| Amarin Pharma, INC. | $19.53 | 2023 | |
| Chiesi USA, INC. | $18.52 | 2022 | |
| Altathera Pharmaceuticals LLC | $17.97 | 2024 | Sotalol Hydrochloride |
| Novo Nordisk INC | $17.11 | 2022 | |
| Kiniksa Pharmaceuticals, Ltd. | $16.92 | 2023 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $15.61 | 2023 | Opsumit, Uptravi |
| Bayer Healthcare Pharmaceuticals INC. | $14.22 | 2023 | |
| Lilly USA, LLC | $13.33 | 2024 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Balaez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.